Drugs / TMP-SMX
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03637400 | Nov 2018 → Feb 2024 | methicillin-resistant staphylococcus aureus infectious disease, skin infection | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase not applicable2 trials · 1 missed | ||||||
| — | NCT05823467 | Jun 2023 → Jul 2026 | breast cancer | University of Alberta | Terminated | No outcome recorded |
| — | NCT00469274 | May 2007 → Dec 2009 | pertussis | Vanderbilt University | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TMP-SMX | “TMP-SMX DS po BID for 14 days” NCT00469274 ↗ |
| Known as | Trimethoprim / Sulfamethoxazole | “Trimethoprim / Sulfamethoxazole” NCT05823467 ↗ |
| Route | Oral | “TMP-SMX DS po BID for 14 days” NCT00469274 ↗ |